Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Law

Showing results (111-120 of 278) with videos related to

Pageof 28
Sort By:
Scientific Reports|September 9, 2017
Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individualsDaniel D Murray, Kazuo Suzuki, Matthew Law, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2007
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulationAlan Winston, Patrick W G Mallon, Claudette Satchell, et al.
Vaccine|January 25, 2011
Trends in anal cancer in Australia, 1982-2005Fengyi Jin, Alicia N Stein, E Lynne Conway, et al.
Plos One|October 15, 2015
Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control StudyDaniel D Murray, Kazuo Suzuki, Matthew Law, et al.
AIDS (London, England)|April 6, 2019
Incidence and time trends of anal cancer among people living with HIV in AustraliaFengyi Jin, Claire M Vajdic, Matthew Law, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2019
Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIVRosan A van Zoest, Matthew Law, Caroline A Sabin, et al.
Vox Sanguinis|May 24, 2022
Risk of variant Creutzfeldt-Jakob disease transmission by blood transfusion in AustraliaHamish McManus, Clive R Seed, Veronica C Hoad, et al.
Vaccine|August 10, 2017
Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effectiveLei Zhang, David G Regan, Jason J Ong, et al.
Lancet (London, England)|February 14, 2004
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trialAndrew Carr, Cassy Workman, Dianne Carey, et al.
Heart (British Cardiac Society)|November 26, 2011
Granulocyte colony stimulating factor in chronic angina to stimulate neovascularisation: a placebo controlled crossover trialSharon Chih, Peter S Macdonald, Jane A McCrohon, et al.
Pageof 28

Showing results (111-120 of 278) with videos related to

Sort By:
Pageof 28
Scientific Reports|September 9, 2017
Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individualsDaniel D Murray, Kazuo Suzuki, Matthew Law, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2007
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulationAlan Winston, Patrick W G Mallon, Claudette Satchell, et al.
Vaccine|January 25, 2011
Trends in anal cancer in Australia, 1982-2005Fengyi Jin, Alicia N Stein, E Lynne Conway, et al.
Plos One|October 15, 2015
Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control StudyDaniel D Murray, Kazuo Suzuki, Matthew Law, et al.
AIDS (London, England)|April 6, 2019
Incidence and time trends of anal cancer among people living with HIV in AustraliaFengyi Jin, Claire M Vajdic, Matthew Law, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2019
Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIVRosan A van Zoest, Matthew Law, Caroline A Sabin, et al.
Vox Sanguinis|May 24, 2022
Risk of variant Creutzfeldt-Jakob disease transmission by blood transfusion in AustraliaHamish McManus, Clive R Seed, Veronica C Hoad, et al.
Vaccine|August 10, 2017
Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effectiveLei Zhang, David G Regan, Jason J Ong, et al.
Lancet (London, England)|February 14, 2004
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trialAndrew Carr, Cassy Workman, Dianne Carey, et al.
Heart (British Cardiac Society)|November 26, 2011
Granulocyte colony stimulating factor in chronic angina to stimulate neovascularisation: a placebo controlled crossover trialSharon Chih, Peter S Macdonald, Jane A McCrohon, et al.
Pageof 28